Streamlining Prior Authorization for Specialty Drugs: Beovu and Dermatology Considerations

While Beovu (brolucizumab) is primarily indicated for ophthalmological conditions, its status as a high-volume prior authorization target highlights common challenges faced by dermatology practices managing complex specialty drug approvals. Klivira automates prior authorization for a wide range of specialty medications, ensuring efficient workflows even for drugs like Beovu, should they enter a dermatology practice's scope.

Dermatology practices frequently navigate complex prior authorization requirements for specialty medications, biologics, and advanced procedures. While Beovu (brolucizumab) is primarily indicated for ophthalmological conditions, its high prior authorization volume across commercial, Medicare Advantage, and Medicaid managed care plans underscores the universal need for efficient PA management for any specialty drug. Klivira empowers dermatology clinics to streamline these processes, reducing administrative burden and accelerating patient access.

Navigating Specialty Drug Prior Authorization in Dermatology

Dermatology practices routinely manage prior authorizations for high-cost biologics, specialty topicals, and advanced procedures like Mohs surgery. The operational complexities of these PAs, including periodic re-authorization cycles for chronic treatments and the distinction between medical and pharmacy benefits, create significant administrative overhead. Klivira provides a robust solution to address these challenges, ensuring a consistent and efficient PA workflow.

Beovu and the Broader Specialty Drug Prior Authorization Landscape

Beovu (brolucizumab), an anti-VEGF therapy, is a high-volume prior authorization target within ophthalmology. While not a typical dermatological medication, its PA profile illustrates the stringent payer requirements common across all specialty drugs. These often include detailed clinical documentation, adherence to step therapy protocols, and specific diagnostic criteria, all of which demand precise, efficient handling regardless of the clinical specialty.

Essential Documentation for Dermatology Specialty Drug Prior Authorizations

Diagnosis confirmation with severity scores (e.g., PASI, EASI, BSA for psoriasis/atopic dermatitis).
Documentation of prior topical therapy trials and conventional systemic therapy (e.g., methotrexate) where applicable.
Evidence of necessary pre-biologic screenings (e.g., TB, hepatitis) in accordance with AAD Clinical Guidelines.
Age-appropriate criteria for specific biologic indications.
Site and tumor type specifics for procedures like Mohs surgery, aligning with AAD Appropriate Use Criteria.
Distinction between clinic-administered versus home self-injection, impacting benefit routing.

Mitigating Common Prior Authorization Denial Risks in Dermatology

Dermatology practices frequently encounter denials due to issues like undocumented step therapy compliance for biologics, lack of severity scores, or discrepancies with Mohs Appropriate Use Criteria. Klivira's platform employs AAD-guideline-aware logic to proactively identify and flag missing documentation, ensuring all payer requirements are met before submission. This significantly reduces the likelihood of denials and appeals.

Klivira: Intelligent Automation for Dermatology Prior Authorizations

Klivira integrates directly with EMRs to automate data extraction and submission for prior authorizations across all major payer portals and channels, including X12 278 and ePA. For dermatology, this means efficient management of high-volume biologic PAs, validation against AAD guidelines for conditions like psoriasis and atopic dermatitis, and streamlined re-authorization workflows. Our platform adapts to payer-specific rules, minimizing manual effort and accelerating approval times for specialty drugs, regardless of their primary indication.

Enhancing Patient Access and Revenue Cycle for Dermatology

By automating the prior authorization process, Klivira helps dermatology practices reduce administrative costs, reallocate staff to patient care, and improve overall revenue cycle efficiency. Faster PA approvals mean quicker access to essential treatments for patients, improving outcomes and satisfaction. Our solution provides transparent tracking and analytics, giving revenue cycle directors clear insights into PA performance.

Frequently asked questions

Is Beovu commonly prescribed in dermatology?

Beovu (brolucizumab) is primarily indicated for ophthalmological conditions such as wet age-related macular degeneration, not for dermatological conditions. While not a typical dermatology medication, its high prior authorization volume highlights the complex PA landscape for all specialty drugs.

How does Klivira handle prior authorizations for biologics in dermatology?

Klivira automates the prior authorization process for biologics used in dermatology by integrating with EMRs and payer portals. Our platform applies AAD-guideline-aware logic for conditions like psoriasis and atopic dermatitis, validates step therapy requirements, and manages periodic re-authorization cycles to expedite approvals.

What are the typical challenges for Mohs surgery prior authorizations?

Mohs surgery prior authorizations often face challenges related to documenting the specific site and tumor type to align with payer policies and AAD Appropriate Use Criteria. Klivira's system helps validate these criteria, ensuring comprehensive documentation is submitted to minimize denials.

Does Klivira integrate with my EMR for dermatology PAs?

Yes, Klivira offers robust integration capabilities with leading EMR systems. This allows for seamless data extraction directly from patient charts, reducing manual data entry and ensuring accuracy for prior authorization submissions across all dermatological specialty drugs and procedures.

How does Klivira address step therapy requirements for dermatological conditions?

Klivira's platform incorporates intelligent logic to guide practices through payer-specific step therapy requirements for dermatological conditions. It prompts for necessary documentation, such as trials of prior topical or conventional systemic therapies, ensuring compliance and reducing the risk of denials related to unmet step therapy protocols.